JP2018070625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018070625A5 JP2018070625A5 JP2017224413A JP2017224413A JP2018070625A5 JP 2018070625 A5 JP2018070625 A5 JP 2018070625A5 JP 2017224413 A JP2017224413 A JP 2017224413A JP 2017224413 A JP2017224413 A JP 2017224413A JP 2018070625 A5 JP2018070625 A5 JP 2018070625A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acids
- seq
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 102100037241 Endoglin Human genes 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 108010036395 Endoglin Proteins 0.000 claims 21
- 150000001413 amino acids Chemical class 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000010494 dissociation reaction Methods 0.000 claims 8
- 230000005593 dissociations Effects 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 208000019622 heart disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000036490 Arterial inflammations Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000027796 Blood pressure disease Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims 2
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 102000052974 human BMP10 Human genes 0.000 claims 2
- 102000046041 human GDF2 Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 238000011277 treatment modality Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 206010017982 Gastrointestinal necrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 claims 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000014471 histiocytoid cardiomyopathy Diseases 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000007171 neuropathology Effects 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477585P | 2011-04-20 | 2011-04-20 | |
| US61/477,585 | 2011-04-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506553A Division JP6250533B2 (ja) | 2011-04-20 | 2012-04-19 | エンドグリンポリペプチドおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020134862A Division JP7097930B2 (ja) | 2011-04-20 | 2020-08-07 | エンドグリンポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018070625A JP2018070625A (ja) | 2018-05-10 |
| JP2018070625A5 true JP2018070625A5 (cg-RX-API-DMAC7.html) | 2018-10-11 |
| JP6803315B2 JP6803315B2 (ja) | 2020-12-23 |
Family
ID=46000405
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506553A Expired - Fee Related JP6250533B2 (ja) | 2011-04-20 | 2012-04-19 | エンドグリンポリペプチドおよびその使用 |
| JP2017224413A Expired - Fee Related JP6803315B2 (ja) | 2011-04-20 | 2017-11-22 | エンドグリンポリペプチドおよびその使用 |
| JP2020134862A Active JP7097930B2 (ja) | 2011-04-20 | 2020-08-07 | エンドグリンポリペプチドおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506553A Expired - Fee Related JP6250533B2 (ja) | 2011-04-20 | 2012-04-19 | エンドグリンポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020134862A Active JP7097930B2 (ja) | 2011-04-20 | 2020-08-07 | エンドグリンポリペプチドおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9932386B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2699590B8 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6250533B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN108178789B (cg-RX-API-DMAC7.html) |
| AU (4) | AU2012245439B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2833747C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2699590T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012145539A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| AU2012245439B2 (en) | 2011-04-20 | 2017-04-06 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
| WO2013019805A1 (en) | 2011-08-01 | 2013-02-07 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| CA2962277C (en) | 2013-09-20 | 2021-12-07 | Tufts Medical Center, Inc. | Methods and compositions for reducing cardiac damage and other conditions |
| CN105899225A (zh) * | 2013-10-25 | 2016-08-24 | 阿塞勒隆制药公司 | 用于治疗纤维化疾病的内皮联蛋白肽 |
| CA2931309C (en) * | 2013-11-21 | 2022-06-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| JP6836400B2 (ja) | 2014-03-28 | 2021-03-03 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | 乳がんおよび卵巣がんワクチン |
| GB201412290D0 (en) | 2014-07-10 | 2014-08-27 | Cambridge Entpr Ltd | Novel use |
| EP3174550B1 (en) | 2014-08-01 | 2020-01-29 | The Brigham and Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| CN108348578B (zh) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| CN110498851B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物及应用 |
| WO2017176938A1 (en) * | 2016-04-06 | 2017-10-12 | Acceleron Pharma, Inc. | Bmprii polypeptides and uses thereof |
| WO2018009624A1 (en) * | 2016-07-07 | 2018-01-11 | Acceleron Pharma Inc. | Tgf-beta superfamily heteromultimers and uses thereof |
| RS64315B1 (sr) | 2017-05-04 | 2023-08-31 | Acceleron Pharma Inc | Fuzioni proteini tgf-beta receptora tipa ii i njihove upotrebe |
| US20210107959A1 (en) * | 2018-01-03 | 2021-04-15 | Acceleron Pharma Inc. | Single-arm co-receptor fusion proteins and uses thereof |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| US20220195500A1 (en) * | 2019-04-26 | 2022-06-23 | Vanderbilt University | Probes for detecting rna and methods of use thereof |
| US20220195056A1 (en) * | 2019-08-07 | 2022-06-23 | Icahn School Of Medicine At Mount Sinai | Method of treating keloids |
| EP4081240A4 (en) * | 2019-12-03 | 2023-12-06 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION |
| WO2021167952A2 (en) * | 2020-02-20 | 2021-08-26 | The Feinstein Institutes For Medical Research | Agonist antibodies against endoglin and uses thereof |
| KR20220021207A (ko) * | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| US20220233714A1 (en) * | 2021-01-27 | 2022-07-28 | Vanderbilt University | Nanogold-dna bioconjugates and methods of use thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| AU5541094A (en) | 1992-10-30 | 1994-05-24 | Consejo Superior De Investigaciones Cientificas | Compositions and methods for modifying the regulatory activity of tgf-beta |
| US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US6423501B2 (en) | 1996-12-13 | 2002-07-23 | Beth Israel Deaconess Medical Center | Calcium-independent negative regulation by CD81 of receptor signaling |
| MX9701946A (es) | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
| SI1325932T1 (cg-RX-API-DMAC7.html) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EP1695985B1 (en) | 1997-04-07 | 2011-03-09 | Genentech, Inc. | Methods for forming humanised antibodies by random mutagenesis |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| AU7467898A (en) | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| KR20080068151A (ko) | 2000-06-23 | 2008-07-22 | 바이엘 쉐링 파마 악티엔게젤샤프트 | ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ) |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1638941B1 (en) | 2003-05-22 | 2010-06-02 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US20050186208A1 (en) | 2003-05-30 | 2005-08-25 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20090170767A1 (en) | 2006-05-31 | 2009-07-02 | Beth Israel Deaconess Medical Center | Soluble Endoglin Compounds for the Treatment and Prevention of Cancer |
| US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| EP3181580A1 (en) * | 2006-11-02 | 2017-06-21 | Acceleron Pharma Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| WO2008151078A1 (en) * | 2007-06-01 | 2008-12-11 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| US20100210713A1 (en) | 2009-01-16 | 2010-08-19 | The General Hospital Corporation | Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| EP3384964B1 (en) * | 2009-03-30 | 2020-03-25 | Acceleron Pharma Inc. | Bmp-alk3 antagonists and uses for promoting bone growth |
| WO2010128158A1 (en) * | 2009-05-08 | 2010-11-11 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
| US8795663B2 (en) * | 2010-01-12 | 2014-08-05 | Beth Israel Deaconess Medical Center, Inc. | Soluble endoglin and uses thereof |
| AU2012245439B2 (en) | 2011-04-20 | 2017-04-06 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
| WO2013019805A1 (en) | 2011-08-01 | 2013-02-07 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
| CA2962277C (en) | 2013-09-20 | 2021-12-07 | Tufts Medical Center, Inc. | Methods and compositions for reducing cardiac damage and other conditions |
| CN105899225A (zh) | 2013-10-25 | 2016-08-24 | 阿塞勒隆制药公司 | 用于治疗纤维化疾病的内皮联蛋白肽 |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
-
2012
- 2012-04-19 AU AU2012245439A patent/AU2012245439B2/en not_active Ceased
- 2012-04-19 CN CN201810139884.7A patent/CN108178789B/zh not_active Expired - Fee Related
- 2012-04-19 US US14/112,620 patent/US9932386B2/en active Active
- 2012-04-19 JP JP2014506553A patent/JP6250533B2/ja not_active Expired - Fee Related
- 2012-04-19 DK DK12717013.2T patent/DK2699590T3/en active
- 2012-04-19 CN CN201280030070.0A patent/CN103781798B/zh not_active Expired - Fee Related
- 2012-04-19 CN CN201810139885.1A patent/CN108341863A/zh active Pending
- 2012-04-19 EP EP12717013.2A patent/EP2699590B8/en active Active
- 2012-04-19 EP EP19150039.6A patent/EP3549952A1/en active Pending
- 2012-04-19 WO PCT/US2012/034295 patent/WO2012145539A1/en not_active Ceased
- 2012-04-19 CA CA2833747A patent/CA2833747C/en active Active
-
2017
- 2017-03-13 AU AU2017201711A patent/AU2017201711B2/en not_active Ceased
- 2017-11-22 JP JP2017224413A patent/JP6803315B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-28 US US15/908,644 patent/US10981972B2/en active Active
-
2019
- 2019-07-11 AU AU2019204979A patent/AU2019204979B2/en not_active Ceased
-
2020
- 2020-08-07 JP JP2020134862A patent/JP7097930B2/ja active Active
- 2020-09-30 AU AU2020244456A patent/AU2020244456A1/en not_active Abandoned
-
2021
- 2021-03-18 US US17/205,573 patent/US20210300991A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018070625A5 (cg-RX-API-DMAC7.html) | ||
| JP7365715B2 (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| JP7725551B2 (ja) | アクチビンｉｉａ型受容体変異体を含む医薬組成物 | |
| JP2020506693A5 (cg-RX-API-DMAC7.html) | ||
| RU2725812C2 (ru) | Конструкции полиспецифических антител | |
| JP5996631B2 (ja) | ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤 | |
| US20110250215A1 (en) | Structurally-related relaxin-fusion proteins with extended in vivo half-lives | |
| AU2018201273A1 (en) | Fibronectin based scaffold domain proteins that bind to myostatin | |
| CN106687478B (zh) | 新的抗人Tie-2抗体 | |
| CN106661128A (zh) | 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物 | |
| JP2016510743A (ja) | 抗ｔｎｆ−抗ｉｌ−１７二重特異性抗体 | |
| JP6431844B2 (ja) | Ｔｎｆｒ：ｆｃ融合プロテインの安定な医薬組成物 | |
| EP3013366A1 (en) | Combination therapy using a factor xii inhibitor and a c1-inhibitor | |
| WO2022072882A1 (en) | Methods of using activin receptor type ii variants | |
| JP2018537093A5 (cg-RX-API-DMAC7.html) | ||
| JP2008521426A5 (cg-RX-API-DMAC7.html) | ||
| JP2017531613A5 (cg-RX-API-DMAC7.html) | ||
| WO2017059371A1 (en) | Treatment of bile acid disorders | |
| JP2024546877A (ja) | ヘテロ二量体リラキシン融合物を使用した治療 | |
| JP2023524866A (ja) | 抗ｉｌ－３３抗体の処方物 | |
| US20230265211A1 (en) | Anti-protein s single-domain antibodies and polypeptides comprising thereof | |
| US20250304675A1 (en) | Compositions and methods for treating ischemic heart disease | |
| WO2024121362A1 (en) | Dosing regimens using heterodimeric relaxin fusions | |
| AU2022276188A1 (en) | Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof | |
| RU2022122493A (ru) | Антитело против адреномедуллина (adm), или фрагмент антитела против adm, или анти-adm не-ig каркас для применения в терапии или профилактике шока |